サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1409639

非アルコール性脂肪肝炎バイオマーカーの世界市場レポート 2024年

Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.85円
非アルコール性脂肪肝炎バイオマーカーの世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

非アルコール性脂肪肝炎バイオマーカーの市場規模は近年急激に拡大しています。2023年の11億1,000万米ドルから2024年には13億9,000万米ドルへと、CAGR25.6％で拡大します。過去一定期間の成長は、糖尿病やメタボリックシンドローム、認知度向上やスクリーニングの取り組み、肝生検の限界、規制当局の後押し、個別化医療への移行、非アルコール性脂肪性肝炎（NASH）の臨床試験などの要因によるものと考えられます。

肝がんの有病率の増加が予想されることから、非アルコール性脂肪肝炎バイオマーカー市場の成長が期待されます。肝臓がんは、肝臓自体に発生したもの（原発性肝がん）であれ、体の他の部位から転移したもの（続発性または転移性肝がん）であれ、早期発見、病勢進行モニタリング、治療効果評価のために非アルコール性脂肪肝炎（NASH）バイオマーカーの使用が必要です。これらのバイオマーカーは予後に関する情報も提供するため、侵襲的な処置への依存を減らすことができます。例えば、2022年10月にJournal of Hepatology誌で報告された最近の研究では、肝がん症例の約56％がB型肝炎ウイルス（HBV）に起因するとされています。その結果、肝臓がんの有病率の増加が非アルコール性脂肪肝炎バイオマーカー市場を推進する重要な要因となっています。

2023年の非アルコール性脂肪肝炎バイオマーカー市場で最大の地域は北米です。アジア太平洋は、予測期間中に非アルコール性脂肪肝炎バイオマーカー市場で最も急成長する地域となる見込みです。非アルコール性脂肪肝炎バイオマーカー市場レポートの対象地域は、アジア太平洋,西欧,東欧,北米,南米,中東,アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 非アルコール性脂肪肝炎バイオマーカー市場の特徴

第3章 非アルコール性脂肪肝炎バイオマーカー市場の動向と戦略

第4章 非アルコール性脂肪肝炎バイオマーカー市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の非アルコール性脂肪肝炎バイオマーカー市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 非アルコール性脂肪肝炎バイオマーカー市場セグメンテーション

  • 世界の非アルコール性脂肪肝炎バイオマーカー市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 肝線維症バイオマーカー
  • 血清バイオマーカー
  • 酸化ストレスバイオマーカー
  • アポトーシスバイオマーカー
  • その他のタイプ
  • 世界の非アルコール性脂肪肝炎バイオマーカー市場、疾患別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 高血圧
  • 心臓病
  • 高血中脂質
  • 2型糖尿病
  • 肥満
  • 世界の非アルコール性脂肪肝炎バイオマーカー市場、最終用途別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 研究機関と学術機関
  • 診断センター
  • 製薬会社と製薬会社と調査受託機関（CRO）
  • 病院と診療所
  • その他の最終用途

第7章 非アルコール性脂肪肝炎バイオマーカー市場の地域および国分析

  • 世界の非アルコール性脂肪肝炎バイオマーカー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の非アルコール性脂肪肝炎バイオマーカー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の非アルコール性脂肪肝炎バイオマーカー市場

第9章 中国の非アルコール性脂肪肝炎バイオマーカー市場

第10章 インドの非アルコール性脂肪肝炎バイオマーカー市場

第11章 日本の非アルコール性脂肪肝炎バイオマーカー市場

第12章 オーストラリアの非アルコール性脂肪肝炎バイオマーカー市場

第13章 インドネシアの非アルコール性脂肪肝炎バイオマーカー市場

第14章 韓国の非アルコール性脂肪肝炎バイオマーカー市場

第15章 西欧の非アルコール性脂肪肝炎バイオマーカー市場

第16章 英国の非アルコール性脂肪肝炎バイオマーカー市場

第17章 ドイツの非アルコール性脂肪肝炎バイオマーカー市場

第18章 フランスの非アルコール性脂肪肝炎バイオマーカー市場

第19章 イタリアの非アルコール性脂肪肝炎バイオマーカー市場

第20章 スペインの非アルコール性脂肪肝炎バイオマーカー市場

第21章 東欧の非アルコール性脂肪肝炎バイオマーカー市場

第22章 ロシアの非アルコール性脂肪肝炎バイオマーカー市場

第23章 北米の非アルコール性脂肪肝炎バイオマーカー市場

第24章 米国の非アルコール性脂肪肝炎バイオマーカー市場

第25章 カナダの非アルコール性脂肪肝炎バイオマーカー市場

第26章 南米の非アルコール性脂肪肝炎バイオマーカー市場

第27章 ブラジルの非アルコール性脂肪肝炎バイオマーカー市場

第28章 中東の非アルコール性脂肪肝炎バイオマーカー市場

第29章 アフリカの非アルコール性脂肪肝炎バイオマーカー市場

第30章 非アルコール性脂肪肝炎バイオマーカー市場の競合情勢と企業プロファイル

  • 非アルコール性脂肪肝炎バイオマーカー市場の競合情勢
  • 非アルコール性脂肪肝炎バイオマーカー市場企業プロファイル
    • Genfit SA
    • Prometheus Laboratories Inc.
    • Siemens Medical Solutions USA Inc.
    • BioPredictive
    • Quest Diagnostics

第31章 世界の非アルコール性脂肪肝炎バイオマーカー市場の競合ベンチマーキング

第32章 世界の非アルコール性脂肪肝炎バイオマーカー市場競争力ダッシュボード

第33章 非アルコール性脂肪肝炎バイオマーカー市場における主要な合併と買収

第34章 非アルコール性脂肪肝炎バイオマーカー市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11177

“Non-Alcoholic Steatohepatitis Biomarkers Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis biomarkers? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The non-alcoholic steatohepatitis biomarkers market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Type: Hepatic Fibrosis Biomarkers; Serum Biomarkers; Oxidative Stress Biomarkers; Apoptosis Biomarkers; Other Types
  • 2) By Disease: Hypertension; Heart Disease; High Blood Lipid; Type 2 Diabetes; Obesity
  • 3) By End Use: Research Institutes And Academics; Diagnostic Centers; Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs); Hospitals And Clinics; Other End-Uses
  • Companies Mentioned: Genfit SA; Prometheus Laboratories Inc.; Siemens Medical Solutions USA Inc.; BioPredictive; Quest Diagnostics
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Non-alcoholic steatohepatitis (NASH) is a form of liver inflammation and damage resulting from the accumulation of fat in the liver. NASH biomarkers serve as diagnostic tools to evaluate the severity of non-alcoholic steatohepatitis and assess liver damage. This condition can lead to inflammation and damage to liver cells, potentially causing cirrhosis (liver scarring) and liver failure. Biomarkers, in this context, are specific qualities that can be tested to reveal pathogenic processes, healthy biological processes, or reactions to exposure or treatment.

The primary types of NASH biomarkers include hepatic fibrosis biomarkers, serum biomarkers, oxidative stress biomarkers, apoptosis biomarkers, and others. Hepatic fibrosis biomarkers are specifically designed to assess hepatic fibrosis, an exaggerated wound healing response leading to excessive connective tissue formation in the liver. These biomarkers are utilized in the treatment of various diseases, including hypertension, heart disease, high blood lipids, type 2 diabetes, and obesity. NASH biomarkers find applications across various end-users, including research institutes and academics, diagnostic centers, pharmaceutical companies and contract research organizations (CROs), hospitals and clinics, among others.

The non-alcoholic steatohepatitis biomarkers market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis biomarkers market statistics, including non-alcoholic steatohepatitis biomarkers industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis biomarkers market share, detailed non-alcoholic steatohepatitis biomarkers market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis biomarkers industry. This non-alcoholic steatohepatitis biomarkers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis biomarkers market size has grown exponentially in recent years. It will grow from $1.11 billion in 2023 to $1.39 billion in 2024 at a compound annual growth rate (CAGR) of 25.6%. The growth during the historical period can be ascribed to factors such as diabetes and metabolic syndrome, awareness and screening initiatives, limitations in liver biopsy, regulatory backing, a transition towards personalized medicine, and clinical trials in nonalcoholic steatohepatitis (NASH).

The non-alcoholic steatohepatitis biomarkers market size is expected to see exponential growth in the next few years. It will grow to $3.2 billion in 2028 at a compound annual growth rate (CAGR) of 23.1%. The growth anticipated in the forecast period can be linked to the emergence of new therapies, the extension of precision medicine approaches, initiatives by patient advocacy groups, the integration of multi-omics data, and heightened patient engagement. Key trends in the forecast period encompass telemedicine and remote monitoring, innovative diagnostic platforms, global research collaborations, technological advancements in biomarker discovery, the incorporation of artificial intelligence (AI), and the inclusion of imaging biomarkers.

The anticipated increase in the prevalence of liver cancer is expected to drive the growth of the non-alcoholic steatohepatitis biomarkers market. Liver cancer, whether originating in the liver itself (primary liver cancer) or spreading from other parts of the body (secondary or metastatic liver cancer), necessitates the use of non-alcoholic steatohepatitis (NASH) biomarkers for early detection, disease progression monitoring, and treatment response assessment. These biomarkers also provide prognostic information, reducing the reliance on invasive procedures. For example, recent studies, as reported by the Journal of Hepatology in October 2022, attribute about 56% of liver cancer cases to the hepatitis B virus (HBV). Consequently, the growing prevalence of liver cancer is a key factor propelling the non-alcoholic steatohepatitis biomarkers market.

The increasing demand for personalized medicine is poised to fuel the growth of the non-alcoholic steatohepatitis biomarkers market. Personalized medicine involves tailoring medical decisions, interventions, and drug therapies to individual patients. In the context of non-alcoholic steatohepatitis (NASH) biomarkers, personalized medicine facilitates precise and individualized diagnosis, the development of tailored treatment strategies, optimized drug selection, treatment response monitoring, and minimization of adverse effects. Reports from October 2022 indicate over 75,000 genetic testing products and 300 personalized medicines, highlighting the growing demand for personalized medicine and its role in driving the non-alcoholic steatohepatitis biomarkers market.

Technological advancements have emerged as a prominent trend in the non-alcoholic steatohepatitis biomarkers market, with major companies focusing on innovative solutions to enhance their market position. In October 2022, GENFIT and LabCorp entered a five-year exclusive licensing deal for GENFIT's NIS4 technology, a multi-biomarker-based algorithm designed to identify patients at risk of non-alcoholic steatohepatitis (NASH) and significant to advanced fibrosis. LabCorp will develop and commercialize a blood-based molecular diagnostic test utilizing NIS4 technology in the United States and Canada. This partnership aims to provide widespread access to healthcare professionals, demonstrating the importance of technological advancements in driving the non-alcoholic steatohepatitis biomarkers market.

Major companies in the non-alcoholic steatohepatitis biomarkers market are also focusing on innovative products, such as NASHnext, to boost revenues. NASHnext, launched by Genfit S.A. in May 2021, utilizes NIS4 technology, a patented diagnostic tool for detecting NASH and significant fibrosis. This revolutionary blood-based molecular biomarker test helps identify patients with NASH and assess the severity of the condition. The test combines four distinct NASH-associated biomarkers to provide a comprehensive score representing both fibrosis and NASH activity, aiming to transform the diagnosis and management of nonalcoholic steatohepatitis (NASH).

In June 2022, Novo Nordisk A/S partnered with Echosens SA to promote early diagnosis of non-alcoholic steatohepatitis (NASH) and raise awareness among patients, medical professionals, and other stakeholders. Echosens SA, a France-based manufacturer, specializes in therapeutic monitoring and diagnostic devices.

Major companies operating in the non-alcoholic steatohepatitis biomarkers market report are Genfit SA, Prometheus Laboratories Inc., Siemens Medical Solutions USA Inc., BioPredictive, Quest Diagnostics, AstraZeneca Plc., Laboratory Corporation of America Holdings, Pfizer Inc., Bristol-Myers Squibb Company, NGM Biopharmaceuticals Inc., Gilead Sciences Inc., Perspectum Diagnostics Ltd., One Way Liver SL, Enterome SA, Echosens SA, Cisbio Bioassays SAS, Celerion Inc., Xeptagen SpA, Boehringer Ingelheim GmbH Inc., Exalenz Bioscience Ltd., Novartis AG, Novo Nordisk A/S, Allergan PLC., Glympse Bio, HistoIndex Pte Ltd, Cirius Therapeutics, Intercept Pharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals, Galmed Pharmaceuticals, Conatus Pharmaceuticals, Immuron Ltd, Metacrine .

North America was the largest region in the non-alcoholic steatohepatitis biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region in the non-alcoholic steatohepatitis biomarkers market during the forecast period. The regions covered in the non-alcoholic steatohepatitis biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the non-alcoholic steatohepatitis biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis biomarkers market consists of sales of biomarkers such as apolipoprotein A1, apolipoprotein B, leptin and adiponectin. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Biomarkers Market Characteristics

3. Non-Alcoholic Steatohepatitis Biomarkers Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Biomarkers Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Non-Alcoholic Steatohepatitis Biomarkers Market Size and Growth

  • 5.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Non-Alcoholic Steatohepatitis Biomarkers Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Non-Alcoholic Steatohepatitis Biomarkers Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Alcoholic Steatohepatitis Biomarkers Market Segmentation

  • 6.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hepatic Fibrosis Biomarkers
  • Serum Biomarkers
  • Oxidative Stress Biomarkers
  • Apoptosis Biomarkers
  • Other Types
  • 6.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity
  • 6.3. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Research Institutes And Academics
  • Diagnostic Centres
  • Pharmaceutical Companies And Pharmaceutical Companies And Contract Research Organizations (CROs)
  • Hospitals And Clinics
  • Other End-Uses

7. Non-Alcoholic Steatohepatitis Biomarkers Market Regional And Country Analysis

  • 7.1. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Non-Alcoholic Steatohepatitis Biomarkers Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market

  • 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Alcoholic Steatohepatitis Biomarkers Market

  • 9.1. China Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 9.2. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Alcoholic Steatohepatitis Biomarkers Market

  • 10.1. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Biomarkers Market

  • 11.1. Japan Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 11.2. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Biomarkers Market

  • 12.1. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market

  • 13.1. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market

  • 14.1. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 14.2. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market

  • 15.1. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 15.2. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Biomarkers Market

  • 16.1. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Biomarkers Market

  • 17.1. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Alcoholic Steatohepatitis Biomarkers Market

  • 18.1. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Biomarkers Market

  • 19.1. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Biomarkers Market

  • 20.1. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market

  • 21.1. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 21.2. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Biomarkers Market

  • 22.1. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Biomarkers Market

  • 23.1. North America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 23.2. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Biomarkers Market

  • 24.1. USA Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 24.2. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Biomarkers Market

  • 25.1. Canada Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 25.2. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Biomarkers Market

  • 26.1. South America Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 26.2. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market

  • 27.1. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market

  • 28.1. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 28.2. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Biomarkers Market

  • 29.1. Africa Non-Alcoholic Steatohepatitis Biomarkers Market Overview
  • 29.2. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By Disease, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Non-Alcoholic Steatohepatitis Biomarkers Market, Segmentation By End Use, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape And Company Profiles

  • 30.1. Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Landscape
  • 30.2. Non-Alcoholic Steatohepatitis Biomarkers Market Company Profiles
    • 30.2.1. Genfit SA
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Prometheus Laboratories Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Siemens Medical Solutions USA Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. BioPredictive
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Quest Diagnostics
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Benchmarking

32. Global Non-Alcoholic Steatohepatitis Biomarkers Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Biomarkers Market

34. Non-Alcoholic Steatohepatitis Biomarkers Market Future Outlook and Potential Analysis

  • 34.1 Non-Alcoholic Steatohepatitis Biomarkers Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Non-Alcoholic Steatohepatitis Biomarkers Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Non-Alcoholic Steatohepatitis Biomarkers Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer